Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state

Molecular Psychiatry

Volumn 22, Issue 6, 2017, Pages 920-930

  Fuchs, T ^a   Jefferson, S J ^a   Hooper, A ^b   Yee, P H ^a   Maguire, J ^c   Luscher, B ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BRAIN EXTRACT; ELONGATION FACTOR 2; ELONGATION FACTOR 2 KINASE; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOSTATIN; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; GABAERGIC RECEPTOR AFFECTING AGENT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE INACTIVATION; IMMUNOHISTOCHEMISTRY; INHIBITORY POSTSYNAPTIC POTENTIAL; INTERNEURON; MALE; MEMORY; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; REAL TIME POLYMERASE CHAIN REACTION; SPATIAL LEARNING; SYNAPTIC INHIBITION; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; WESTERN BLOTTING; ANIMAL; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; GABA AGENTS; GABAERGIC NEURONS; GAMMA-AMINOBUTYRIC ACID; INHIBITORY POSTSYNAPTIC POTENTIALS; INTERNEURONS; KETAMINE; MICE; MICE, TRANSGENIC; RECEPTORS, GABA-A; SOMATOSTATIN; SYNAPTIC TRANSMISSION;

EID: 84994553283     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.188     Document Type: Article

References (81)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105.
2. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653-15658.
3. Miguel-Hidalgo JJ, Waltzer R, Whittom AA, Austin MC, Rajkowska G, Stockmeier CA. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 2010; 127: 230-240.
4. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263: 367-377.
5. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, et al. Reduced cortical gamma-Aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999; 56: 1043-1047.
6. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-Aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64: 193-200.
7. Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, et al. Anterior cingulate cortex gamma-Aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry 2012; 69: 139-149.
8. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, et al. Reduction in occipital cortex gamma-Aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007; 61: 806-812.
9. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009; 65: 792-800.
10. Croarkin PE, Levinson AJ, Daskalakis ZJ. Evidence for GABAergic inhibitory deficits in major depressive disorder. Neurosci Biobehav Rev 2011; 35: 818-825.
11. Klumpers UM, Veltman DJ, Drent ML, Boellaard R, Comans EF, Meynen G, et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010; 37: 565-574.
12. Karolewicz B, Maciag D, O'Dwyer G, Stockmeier CA, Feyissa AM, Rajkowska G. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 2010; 13: 411-420.
13. Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K, et al. Molecular evidence for BDNF- And GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012; 17: 1130-1142.
14. Sibille E, Morris HM, Kota RS, Lewis DA. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 2011; 14: 721-734.
15. Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007; 32: 471-482.
16. Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, et al. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010; 67: 465-470.
17. Hewitt SA, Wamsteeker JI, Kurz EU, Bains JS. Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis. Nat Neurosci 2009; 12: 438-443.
18. MacKenzie G, Maguire J. Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility. Epilepsy Res 2015; 109: 13-27.
19. Liu ZP, Song C, Wang M, He Y, Xu XB, Pan HQ, et al. Chronic stress impairs GABAergic control of amygdala through suppressing the tonic GABAA receptor currents. Mol Brain 2014; 7: 32.
20. Lin LC, Sibille E. Somatostatin, neuronal vulnerability and behavioral emotionality. Mol Psychiatry 2015; 20: 377-387.
21. Maguire J. Stress-induced plasticity of GABAergic inhibition. Front Cell Neurosci 2014; 8: 157.
22. Luscher B, Fuchs T. GABAergic control of depression-related brain states. Adv Pharmacol 2015; 73: 97-144.
23. Bains JS, Wamsteeker Cusulin JI, Inoue W. Stress-related synaptic plasticity in the hypothalamus. Nat Rev Neurosci 2015; 16: 377-388.
24. Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003; 160: 577-579.
25. Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663-665.
26. Hasler G, Neumeister A, van der Veen JW, Tumonis T, Bain EE, Shen J, et al. Normal prefrontal gamma-Aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 2005; 58: 969-973.
27. Shen Q, Lal R, Luellen BA, Earnheart JC, Andrews AM, Luscher B. gamma-Aminobutyric acid-Type A receptor deficits cause hypothalamic-pituitary-Adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol Psychiatry 2010; 68: 512-520.
28. Ren Z, Pribiag H, Jefferson SJ, Shorey M, Fuchs T, Stellwagen D, et al. Bidirectional homeostatic regulation of a depression-related brain state by gammaaminobutyric acidergic deficits and ketamine treatment. Biol Psychiatry 2016; 80: 457-468.
29. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
30. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
31. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41.
32. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481-486.
33. Opal MD, Klenotich SC, Morais M, Bessa J, Winkle J, Doukas D, et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry 2014; 19: 1106-1114.
34. Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM. Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 2007; 55: 648-661.
35. Verpelli C, Piccoli G, Zibetti C, Zanchi A, Gardoni F, Huang K, et al. Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesis. J Neurosci 2010; 30: 5830-5842.
36. Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2013; 73: 1199-1203.
37. Tripp A, Kota RS, Lewis DA, Sibille E. Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol Dis 2011; 42: 116-124.
38. Tripp A, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 1194-1202.
39. Rudy B, Fishell G, Lee S, Hjerling-Leffler J. Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons. Dev Neurobiol 2011; 71: 45-61.
40. Silberberg G, Markram H. Disynaptic inhibition between neocortical pyramidal cells mediated by Martinotti cells. Neuron 2007; 53: 735-746.
41. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol 2008; 286: 75-87.
42. Chiu CQ, Lur G, Morse TM, Carnevale NT, Ellis-Davies GC, Higley MJ. Compartmentalization of GABAergic inhibition by dendritic spines. Science 2013; 340: 759-762.
43. Higley MJ. Localized GABAergic inhibition of dendritic Ca(2+) signalling. Nat Rev Neurosci 2014; 15: 567-572.
44. Maccaferri G, McBain CJ. Passive propagation of LTD to stratum oriens-Alveus inhibitory neurons modulates the temporoammonic input to the hippocampal CA1 region. Neuron 1995; 15: 137-145.
45. Leao RN, Mikulovic S, Leao KE, Munguba H, Gezelius H, Enjin A, et al. OLM interneurons differentially modulate CA3 and entorhinal inputs to hippocampal CA1 neurons. Nat Neurosci 2012; 15: 1524-1530.
46. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X. An excitatory synapse hypothesis of depression. Trends Neurosci 2015; 38: 279-294.
47. Fanselow EE, Richardson KA, Connors BW. Selective, state-dependent activation of somatostatin-expressing inhibitory interneurons in mouse neocortex. J Neurophysiol 2008; 100: 2640-2652.
48. Buzsaki G, Csicsvari J, Dragoi G, Harris K, Henze D, Hirase H. Homeostatic maintenance of neuronal excitability by burst discharges in vivo. Cereb Cortex 2002; 12: 893-899.
49. Klausberger T, Magill PJ, Marton LF, Roberts JD, Cobden PM, Buzsaki G, et al. Brain-state- And cell-Type-specific firing of hippocampal interneurons in vivo. Nature 2003; 421: 844-848.
50. Muller C, Remy S. Dendritic inhibition mediated by O-LM and bistratified interneurons in the hippocampus. Front Synaptic Neurosci 2014; 6: 23.
51. McNaughton N, Kocsis B, Hajos M. Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function?. Behav Pharmacol 2007; 18: 329-346.
52. Essrich C, Lorez M, Benson J, Fritschy J-M, Luscher B. Postsynaptic clustering of major GABA(A) receptor subtypes requires the gamma2 subunit and gephyrin. Nat Neurosci 1998; 1: 563-571.
53. Schweizer C, Balsiger S, Bluethmann H, Mansuy IM, Fritschy JM, Mohler H, et al. The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses. Mol Cell Neurosci 2003; 24: 442-450.
54. Li RW, Yu W, Christie S, Miralles CP, Bai J, Loturco JJ, et al. Disruption of postsynaptic GABA receptor clusters leads to decreased GABAergic innervation of pyramidal neurons. J Neurochem 2005; 95: 756-770.
55. Ren Z, Sahir N, Murakami S, Luellen BA, Earnheart JC, Lal R, et al. Defects in dendrite and spine maturation and synaptogenesis associated with an anxiousdepressive-like phenotype of GABAA receptor-deficient mice. Neuropharmacology 2015; 88: 171-179.
56. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 2001; 1: 4.
57. Shen Q, Fuchs T, Sahir N, Luscher B. GABAergic control of critical developmental periods for anxiety- And depression-related behavior in mice. PLoS One 2012; 7: e47441.
58. Lee V, Maguire J. Impact of inhibitory constraint of interneurons on neuronal excitability. J Neurophysiol 2013; 110: 2520-2535.
59. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185.
60. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809.
61. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523-532.
62. Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 2002; 22: 10883-10890.
63. Gunther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, et al. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-Aminobutyric acid type A receptors. Proc Natl Acad Sci USA 1995; 92: 7749-7753.
64. Taniguchi H, He M, Wu P, Kim S, Paik R, Sugino K, et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron 2011; 71: 995-1013.
65. Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290: 131-134.
66. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988; 95: 298-302.
67. Earnheart JC, Schweizer C, Crestani F, Iwasato T, Itohara S, Mohler H, et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J Neurosci 2007; 27: 3845-3854.
68. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002; 52: 503-528.
69. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 2007; 403: 217-234.
70. Redpath NT, Proud CG. Cyclic AMP-dependent protein kinase phosphorylates rabbit reticulocyte elongation factor-2 kinase and induces calcium-independent activity. Biochem J 1993; 293(Pt 1): 31-34.
71. Diggle TA, Subkhankulova T, Lilley KS, Shikotra N, Willis AE, Redpath NT. Phosphorylation of elongation factor-2 kinase on serine 499 by cAMP-dependent protein kinase induces Ca2+/calmodulin-independent activity. Biochem J 2001; 353(Pt 3): 621-626.
72. Engin E, Stellbrink J, Treit D, Dickson CT. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 2008; 157: 666-676.
73. Hou ZH, Yu X. Activity-regulated somatostatin expression reduces dendritic spine density and lowers excitatory synaptic transmission via postsynaptic somatostatin receptor 4. J Biol Chem 2013; 288: 2501-2509.
74. Soumier A, Sibille E. Opposing effects of acute versus chronic blockade of frontal cortex somatostatin-positive inhibitory neurons on behavioral emotionality in mice. Neuropsychopharmacology 2014; 39: 2252-2262.
75. Pfeffer CK, Xue M, He M, Huang ZJ, Scanziani M. Inhibition of inhibition in visual cortex: the logic of connections between molecularly distinct interneurons. Nat Neurosci 2013; 16: 1068-1076.
76. Somogyi P, Klausberger T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol 2005; 562(Pt 1): 9-26.
77. Gouzer G, Specht CG, Allain L, Shinoe T, Triller A. Benzodiazepine-dependent stabilization of GABA(A) receptors at synapses. Mol Cell Neurosci 2014; 63: 101-113.
78. Harraz MM, Tyagi R, Cortes P, Snyder SH. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 2016; 21: 313-319.
79. Tang J, Xue W, Xia B, Ren L, Tao W, Chen C, et al. Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Sci Rep 2015; 5: 13573.
80. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 2013; 29: 419-423.
81. Heise C, Gardoni F, Culotta L, di Luca M, Verpelli C, Sala C. Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons. Front Cell Neurosci 2014; 8: 35.